Bioxytran, INC: directors' dealings · United States · SEC (Form 4)

About Bioxytran, INC

BIOXYTRAN, INC. (ticker: BIXT) is a U.S.-based biotechnology company with its principal executive offices in Newton, Massachusetts, United States. The company was incorporated in October 2017 and is positioned as a clinical-stage biotech rather than a mature commercial pharmaceutical group. In market communication, it is associated with the U.S. OTCQB venue rather than the NYSE/NASDAQ mainstream listings, which is an important point for investors assessing liquidity, disclosure depth, and financing risk. Bioxytran’s core story is built around platform-oriented drug development. The company initially developed its narrative around oxygen transport and ischemia/hypoxia biology, aiming to address tissue injury caused by blocked blood flow and downstream necrosis. Over time, the pipeline broadened toward carbohydrate-based therapeutics and galectin-targeting programs, with applications spanning infectious disease, inflammation, metabolic health, and related indications. The most visible assets include ProLectin-M, its lead antiviral candidate, and BXT-25, a program associated with oxygen delivery and anti-necrosis use cases. From a competitive standpoint, Bioxytran occupies a highly specialized niche within the small-cap biotech universe. It does not compete with large-cap pharma on scale, manufacturing depth, or commercial reach; instead, its investment case depends on scientific differentiation, intellectual property, and the ability to progress from early or mid-stage clinical evidence to registrational studies and, ultimately, commercialization. For investors, that means the equity is driven less by current sales and more by milestone execution, regulatory feedback, and funding capacity. Recent company updates indicate active pipeline development. In 2026, Bioxytran reported positive dose optimization results for ProLectin-M and said it had entered regulatory discussions for a planned Phase 3 registrational study, including engagement with both U.S. and Indian regulators. The company also announced a commercial distribution agreement for A-SUQAR, a chewable dietary supplement based on its proprietary partially hydrolyzed guar gum formulation, suggesting a modest diversification beyond pure drug development. Overall, BIXT should be viewed as a high-risk, high-upside micro-cap biotech profile. Its valuation is likely to remain highly sensitive to clinical data, regulatory progress, financing events, and insider activity disclosed through SEC Form 4 filings. For French-, Belgian-, and Swiss-based investors, the key question is not near-term profitability, but whether Bioxytran can convert its platform science into credible clinical and commercial value within the U.S. market framework.